Understanding how LATS1/2 proteins help prevent breast cancer
Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis
This study is looking at how certain proteins help control cell growth and stop tumors from forming in breast cancer, with the hope of finding new ways to improve treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11042811 on NIH RePORTER |
What this research studies
This research investigates the Hippo signaling pathway, which plays a crucial role in regulating cell growth and preventing tumor formation, particularly in breast cancer. The study focuses on the LATS1/2 proteins and their interactions with other cellular components to understand how they suppress tumorigenesis. By exploring the upstream regulators of LATS1/2, the research aims to uncover new mechanisms that could lead to innovative cancer therapies. Patients may benefit from insights gained about how to better target breast cancer treatments based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer or those at high risk for developing breast cancer.
Not a fit: Patients with cancers unrelated to breast cancer or those who do not have any genetic predisposition to breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting the Hippo pathway for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Dai, Xiaoming — Beth Israel Deaconess Medical Center
- Study coordinator: Dai, Xiaoming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.